The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...

KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months ...

In human cells, only a small proportion of the information written in genes is used to produce proteins. How does the cell ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Human genes that encode proteins often contain non-coding segments known as introns. Removing introns is crucial for the proper expression of genetic information. Understanding how our cells ...

A new study has uncovered a novel P-type PPR protein, BoYgl-2, which plays a crucial role in chloroplast RNA editing and chlorophyll biosynthesis in ...

Jones Trading initiated coverage on ProQR Therapeutics N.V. (NASDAQ:PRQR) with a Buy rating and set a price target of $11.00, representing significant upside from the current price of $2.19. The ...

JonesResearch analyst Catherine Novack initiated coverage of ProQR Therapeutics (PRQR) with a Buy rating and $11 price target The firm says ...

A new study has uncovered a novel P-type PPR protein, BoYgl-2, which plays a crucial role in chloroplast RNA editing and chlorophyll biosynthesis in cabbage.

Preclinical studies have shown their potential to reduce inflammation and modulate immune responses in diseases like rheumatoid arthritis and lupus.